Riviciclib hydrochloride (P276-00)

Riviciclib hydrochloride (P276-00) is an inhibitor of CDK and CDK1 and related targets used in studies of Cell Cycle Regulation and Apoptosis. In practice, this places the compound in experiments that measure checkpoint control, mitotic progression, and proliferation timing and caspase-associated cell-death signaling and survival decisions in apoptosis, cancer, and cell cycle models.

By inhibiting CDK and CDK1 and related targets, Riviciclib hydrochloride (P276-00) can be used to examine checkpoint control, mitotic progression, and proliferation timing and caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and cell cycle models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving CDK and CDK1 and related targets
• Pathway perturbation studies connected to Cell Cycle Regulation and Apoptosis
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Riviciclib hydrochloride (P276-00) is appropriate when a defined chemical perturbant is needed to connect CDK and CDK1 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and cell cycle models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.